NeOnc halves quarterly loss as it raises $15M and readies glioma data for SNO

NeOnc Technologies Holdings reported a net loss of $4.4M for the three months to 30 September 2026, down from $8.6M in the corresponding quarter of 2025. The figures were published on 5 November. The summary available does not break down what drove the reduction, so it is unclear how far it reflects lower spending or other items.

The company paired the numbers with an update on its two neuro-oncology candidates. For NEO100, an intranasal therapy, it pointed to positive topline results from a Phase 2a study in recurrent IDH1-mutant high-grade glioma. No efficacy figures were available to us, so the strength of the signal cannot be judged. NeOnc intends to present data on NEO100 and NEO212 at the Society for Neuro-Oncology meeting on 13 November.

On NEO212, NeOnc said the US Food and Drug Administration has given written feedback on chemistry, manufacturing and controls, including the planned move to a tablet formulation. The content of the agency's comments was not disclosed.

Balance-sheet and partnership news came alongside. NeOnc closed a $15M registered direct offering and redeemed its Series A preferred stock. In October it also announced a memorandum of understanding with the Abu Dhabi Department of Health; no commercial or regulatory terms were given.